IRS-2 rs1805097 polymorphism is associated with the decreased risk of colorectal cancer.

IRS-2 rs1805097 polymorphism is associated with the decreased risk of colorectal cancer.

Oncotarget. 2017 Feb 15;:

Authors: Yin J, Zhang Z, Zheng H, Xu L

Abstract
Recent studies explored the association between insulin receptor substrate-2 (IRS-2) gene rs1805097 polymorphism and colorectal cancer (CRC) with contradictory findings. Therefore, we conducted a comprehensive meta-analysis by searching the databases of PubMed and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. A total of 5 citations containing 6 case-control studies involving 4,333 cases and 5,333 controls were included. Our data indicated that IRS-2 rs1805097 polymorphism was associated with decreased risk of CRC. Stratification analysis of ethnicity found that rs1805097 polymorphism decreased the risk of CRC among Americans. Stratification analysis of cancer type suggested that this polymorphism decreased the risk of colon cancer. In summary, this meta-analysis indicates that IRS-2 gene rs1805097 polymorphism plays an important role in the pathogenesis of CRC.

PMID: 28212577 [PubMed - as supplied by publisher]

http://ift.tt/2lXAdJb